Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
United States
Local Institution - 0003, Tucson, Arizona Local Institution - 0007, Los Angeles, California Local Institution - 0011, Grand Rapids, Michigan Local Institution - 0004, Sioux Falls, South Dakota Local Institution - 0013, San Antonio, Texas